2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee

Writing Committee; Donald M Lloyd-Jones; Pamela B Morris; Christie M Ballantyne; Kim K Birtcher; Ashleigh M Covington; Sondra M DePalma; Margo B Minissian; Carl E Orringer; Sidney C Smith Jr; Ashley Arana Waring; John T Wilkins

doi:10.1016/j.jacc.2022.07.006

2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee

J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418. doi: 10.1016/j.jacc.2022.07.006. Epub 2022 Aug 25.

Authors

Writing Committee; Donald M Lloyd-Jones, Pamela B Morris, Christie M Ballantyne, Kim K Birtcher, Ashleigh M Covington, Sondra M DePalma, Margo B Minissian, Carl E Orringer, Sidney C Smith Jr, Ashley Arana Waring, John T Wilkins

PMID: 36031461
DOI: 10.1016/j.jacc.2022.07.006

No abstract available

Keywords: ACC Expert Consensus Decision Pathway; LDL dyslipidemia; PCSK9 inhibitors; bempedoic acid cardiovascular disease; cholesterol; ezetimibe; inclisiran; lipids; statins.

Publication types

Practice Guideline

MeSH terms

Anticholesteremic Agents* / therapeutic use
Cardiology*
Cardiovascular Diseases* / drug therapy
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Cholesterol, LDL
Consensus
Ezetimibe
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
United States / epidemiology

Substances

Anticholesteremic Agents
Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ezetimibe